Press Releases

All Releases
View Summary Five Prime Therapeutics Advances FPA008 Into Phase 2 Dose Expansion in Patients with Pigmented Villonodular Synovitis (PVNS)
Thursday, May 12, 2016
PDF 11.8 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
Friday, May 6, 2016
PDF 9.8 KB Add to Briefcase
View Summary Five Prime Announces First Quarter 2016 Results and Provides Business Update
Thursday, May 5, 2016
PDF 25.7 KB Add to Briefcase
View Summary Five Prime Therapeutics to Announce First Quarter 2016 Financial Results and Host Conference Call on May 5
Thursday, April 21, 2016
PDF 9.1 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces New Pre-Clinical Data on FPA144 Presented at the 2016 AACR Annual Meeting
Monday, April 18, 2016
PDF 18.5 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces FPA144 Will Be Featured During a Special Session at the 2016 AACR Annual Meeting
Monday, April 11, 2016
PDF 2.1 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the 2016 Jefferies Immuno-Oncology Summit
Friday, April 1, 2016
PDF 8.9 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present New Pre-Clinical Data on FPA144 at the 2016 AACR Annual Meeting
Wednesday, March 16, 2016
PDF 2.1 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Changes to Board of Directors
Wednesday, March 16, 2016
PDF 11.8 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the Barclays Global Healthcare Conference
Friday, March 11, 2016
PDF 7.0 KB Add to Briefcase
View Summary Five Prime Announces Fourth Quarter and Full Year 2015 Financial Results
Thursday, March 10, 2016
PDF 25.4 KB Add to Briefcase
View Summary Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2015 Financial Results and Host Conference Call on March 10
Friday, February 26, 2016
PDF 6.6 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
Thursday, February 4, 2016
PDF 7.0 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Key Executive Appointments
Monday, February 1, 2016
PDF 11.8 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Preliminary Data From the Dose Escalation Portion of the Phase 1 Trial of FPA144 at the ASCO GI Cancers Symposium
Thursday, January 21, 2016
PDF 15.8 KB Add to Briefcase
View Summary Five Prime Therapeutics Receives FDA Orphan Drug Designation for FPA008 in Pigmented Villonodular Synovitis (PVNS)
Wednesday, January 13, 2016
PDF 8.6 KB Add to Briefcase
View Summary Five Prime Therapeutics Provides Update on FP-1039 Clinical Program
Monday, January 11, 2016
PDF 12.2 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference
Wednesday, January 6, 2016
PDF 9.6 KB Add to Briefcase
View Summary Five Prime Therapeutics Appoints Prominent Immuno-Oncology Thought Leaders to Scientific Advisory Board
Tuesday, January 5, 2016
PDF 13.3 KB Add to Briefcase
View Summary Five Prime Therapeutics Appoints Drug Development Leaders to Board of Directors
Thursday, December 3, 2015
PDF 14.8 KB Add to Briefcase
Showing 61-80 of 191 Page: 1 2 3 4 5 6 7 8 ... 10  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

FPRX (Common Stock)

Exchange
NASDAQ
Price
25.56
Change (%)
-0.20
Volume
409,193

Data as of 4:00 PM ET on Friday, November 17, 2017
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.